Acute Lymphoblastic Leukemia | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2017

Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells. Over the last few years, a number of agents have been launched that have improved treatment outcomes for patients with ALL. These agents include monoclonal antibodies to CD19 (Amgen’s Blincyto) and CD20 (Roche/Genentech’s Rituxan/MabThera); new drugs for T-cell ALL (e.g., Novartis’s Arranon); and TKI agents for Philadelphia chromosome-positive (Ph+ALL (e.g., Novartis’s Gleevec, BMS’s Sprycel, Ariad Pharmaceutical’s Iclusig). Nonetheless, chemotherapies remain the backbone of first-line treatment for ALL. Targeted agents in development—including novel kinase inhibitors, proteasome inhibitors, and immunomodulatory agents, such as chimeric antigen receptor T-cell (CAR-T) therapies—hold promise of providing ALL patients with additional treatment options.

Questions Answered:

  • What is the size of the U.S. and EU5 ALL patient populations, and how will drug treatment rates change over the ten-year forecast period? What are the drug-treatable populations of most commercial interest?
  • What is the current medical practice and management for ALL in the markets under study? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled? What is thought-leader opinion of the CAR-Ts and other emerging therapies? How will these therapies fit into the ALL treatment algorithm in the future?
  • How have the entry of biosimilar rituximab in the EU5 and the generic entry of imatinib in the U.S. and EU5 affected the ALL market?


Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.

Primary research: Six country-specific interviews with thought leaders (medical oncologist-hematologists).

Epidemiology: Diagnosed incident cases of ALL subpopulations; clinical and market-relevant drug-treatable populations.

Population segments in market forecast: First-line adult and pediatric ALL; relapsed/refractory adult and pediatric ALL.

Emerging therapies: Phase III: 3 drugs; Phase II: 3 drugs.

Product Description: Niche & Rare Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Login to access report

launch Related Market Assessment Reports